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Abstract 
Several coupling methods for binding antibodies (Ab) to liposomes have previously been developed. We were interested in examining 
if some of these methods would be suitable for attaching Ab to long-circulating formulations of liposomes (SL), sterically stabilized, with 
poly(ethylene glycol) (PEG). We studied three 'classical' coupling methods in which Ab was attached at the bilayer surface of SL, and 
two new coupling methods in which Ab was attached at the PEG terminus. Parameters examined included binding efficiency, antibody 
surface density, the ability of the immunoliposomes to remote-load the anticancer drug doxorubicin, and the specific binding of the 
resulting immunoliposomes to target cells. The non-covalent biotin-avidin coupling method resulted in low Ab densities at the cell 
surface, as did a coupling method in which maleimide-derivatized Ab was attached to the liposome surface through a thiolated 
phospholipid incorporated into the liposomes. The low levels of Ab achieved in these method was likely due to interference by PEG with 
the access of the Ab to the liposome surface. However, when a maleimide-derivatized Ab was coupled to thiolated PEG, moving the 
coupling reaction away from the liposome surface, very high coupling efficiencies were achieved, and these immunoliposomes achieved 
good specific binding to their target cells. Oxidizing the Fc region of the Ab and coupling it to the PEG terminus through a hydrazone 
bond was a less efficient coupling method, but had the advantage of retaining Ab orientation. Efficient remote-loading of doxorubicin was 
found for immunoliposomes in which Ab was attached at the PEG terminus. 
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Abbreviations: MPS, mononuclear phagocyte system; SL, sterically 
stabilized (Stealth R) liposomes; SIL, sterically stabilized (Stealth R) im- 
munoliposomes formed by attachment of Ab to SL; CL, 'classical' 
liposomes with short circulation half-lives and dose-dependent pharma- 
cokinetics; CIL, immunoliposomes formed from attachment ofAb to CL; 
PL, phospholipid; mPEG-DSPE, methoxypolyethylene glycol of M r 2000 
covalently attached by a carbamate bond to distearoylphos- 
phatidylethanolamine; PDP-PEG-DSPE, N-(3'-(pyridyldithio)propi- 
onoyl)amino-poly(ethylene glycol)-distearoylphosphatidylethanolamine; 
Hz-PEG-DSPE, hydrazide-poly(ethylene glycol)-distearoylphosphatidyl- 
ethanolamine; MPB-DOPE, N-(4'-(4"-maleimidophenyl)butyroyl)- 
dioleoylphosphatidylethanolamine; PDP-DOPE, N-(3'-(pyridyidithio)- 
propionoyl)dioleoylphosphatidylethanolamine; SPDP, N-succinimidyl-3- 
(2-pyridyldithio)proprionate; HSPC, fully hydrogenated soy phosphatidyl- 
choline; SMPB, H-succinimidyl-4-(p-maleimidophenyl)butyrate; Ab, 
polyclonal antibody; mAb, monoclonal antibody; Hepes, N-(2-hydroxy- 
ethyl)piperazine-N'-2-ethanesulfonic acid; Mes, 2-(N-morpholino)ethane- 
sulfonic acid; CHOL, cholesterol; DXR, doxorubicin; Hepes buffer, 25 
mM Hepes, 140 mM NaC1, pH 7.4. 
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1. Introduction 
The utility of liposomes as drug sustained release sys- 
tems or as drug delivery systems for passive targeting is 
now well established, with several iposome-drug formula- 
tions in the clinic or in late clinical trials (reviewed in 
[1-3]). Recently, the description of long-circulating, steri- 
cally stabilized liposomes (SL) containing lipid derivatives 
of polyethylene glycol (PEG) [4-7] has increased the 
opportunities for specific, ligand-mediated, targeting of 
liposome-entrapped drugs to diseased tissues. The proper- 
ties of sterically stabilized liposomes, as compared to 
'classical' liposomes (CL), with their shorter circulation 
half-lives, have been widely reviewed [8-10]. 
One of the most effective ways to specifically target 
cells, e.g., neoplastic cells, is through the high affinity 
binding of monoclonal antibodies (mAb) to their specific 
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antigens. Several methods for binding antibodies (Ab) to 
liposomes have been developed [ 11-18]. Some of the most 
efficient coupling chemistry, originally developed for CL, 
involved conjugation of thiolated Ab to liposomes grafted 
with either thiol or maleimide groups. In these methods, 
thiol groups were generated on the Ab either by interaction 
of the Ab with heterobifunctional crosslinkers uch as 
SPDP or by reducing native disulfide bonds in the whole 
Ab to expose sulfhydryl groups [16-18]. In several studies, 
immunotargeted CL achieved an increased localization in 
cells in vitro and tumours in vivo [19-23]. However, it 
was also observed that 'classical' immunoliposomes (CIL) 
were very rapidly removed from circulation by the cells of 
the mononuclear phagocyte system (MPS) [21,22] which 
greatly reduced the opportunities for their specific binding 
to most target issues in vivo. In order to attach Ab to SL, 
we have explored some established methods, concentrating 
on coupling methodologies involving the thioether bond, 
as well as developed some new coupling methodologies, in 
an effort to overcome these short-comings of CIL. Our aim 
was to develop long-circulating, sterically stabilized, im- 
munoliposomes (SIL) which could lead to significantly 
increased levels of in vivo targeting and to improved 
therapeutic effects. 
To develop a targeted rug delivery system using steri- 
cally stabilized liposomes we began by outlining what we 
felt to be the major criteria for 'ideal' immunoliposomes. 
These criteria fell into two main groups. The first was 
related to optimizing the conjugate chemistry. Ideally, 
coupling methods hould be both simple and rapid, produc- 
ing a stable, non-toxic bond. A wide range of Ab densities 
should be achievable at the liposome surface in order to 
optimize immunoliposome binding to their target cells, as 
each different Ab will have a different affinity for its 
antigen. During conjugation the antibody should retain 
antigen recognition and the liposomes hould not lose their 
structural integrity. The second set of criteria dealt with 
developing sterically stabilized immunoliposomes (SIL) as 
drug delivery systems. Drugs, such as the antineoplastic 
drug doxorubicin, need to be loaded efficiently into the 
SIL and, once at the target site, released at rates which will 
result in improved therapeutic effects over that achievable 
for the free drug. SIL should survive in circulation for 
sufficient ime to find and bind to their targets. Recogni- 
tion of the target cells by the immunoliposomes should not 
be reduced significantly by the associated drugs or by the 
PEG coating at the liposome surface. The carrier should 
not be toxic to the host and the drug-loaded SIL should 
have in vivo therapeutic efficacy. 
We have used two basic strategies for the development 
of SIL (Fig. 1). The first strategy was to adapt he covalent 
Ab conjugation techniques described for CL for use with 
SL. In these procedures, the previously described linker- 
lipids N-(4'-(4"-maleimidophenyl)butyroyl)dioleoyl- 
phosphatidylethanolamine (MPB-DOPE) or N-(3'-(pyrid- 
yldithio)propionoyldioleoylphosphatidylethanolamine 
(PDP-DOPE) were incorporated into liposomes, sterically 
stabilized with mPEG-distearoylphosphatidylethanolamine 
(mPEG-DSPE), and Ab was coupled to the resulting SL to 
form SIL. The second strategy was to develop new cova- 
lent conjugation procedures for coupling Ab to the termi- 
nus of PEG using the novel functionalized PEG-lipids, 
N-(3'-(pyridyldithio)propionoylamino-PEG-DSPE (PDP- 
PEG-DSPE) [23] and hydrazide-PEG-DSPE (Hz-PEG- 
DSPE) [24]. In addition, we have included some data 
comparing a non-covalent (biotin-avidin) method of attach- 
ment of Ab to SL [25] with the covalent methods. In this 
report we have compared the different coupling proce- 
dures, relative to a number of the criteria outlined in the 
previous paragraph, and have shown that the coupling 
procedures which most closely approaches the ideal are 
those in which Ab is coupled at the PEG terminus. In 
addition, we have demonstrated specific binding of SIL, 
coupled to mAb against cancer-associated antigens, to their 
target epitopes on neoplastic ells in vitro. 
2. Materials and methods 
2.1. Mater ia l s  
HSPC, PDP-PEG-DSPE, Hz-PEG-DSPE and mPEG- 
DSPE were generous gifts of SEQUUS Pharmaceuticals 
(formerly Liposome Technology Inc.) (Menlo Park, CA). 
The synthesis of PDP-PEG-DSPE [23], Hz-PEG-DSPE 
[24] and methoxyPEG-DSPE (mPEG-DSPE) [6] has been 
previously described. PEG of molecular weight 2000 was 
used in all PEG-containing compounds. Cholesterol, 
MPB-DOPE, PDP-DOPE and biotinylated PE were pur- 
chased from Avanti Polar Lipids (Alabaster, AL). Sephadex 
G-50, Sephadex G-25, Sepharose CL-4B, SMPB, SPDP, 
avidin (egg), Mes (2-(N-morpholino)ethanesulfonic acid), 
sodium periodate, rabbit anti-bovine IgG (whole molecule) 
antibody, mouse anti-rabbit (whole molecule) horseradish 
peroxidase conjugate, N-hydroxysuccinimide-biotin, 
bovine IgG, sheep IgG and Tes (N-tris(hydroxy- 
methyl)methyl-2-aminoethane sulfonic acid) were pur- 
chased from Sigma (St. Louis, MO). Doxorubicin (DXR, 
Adriamycin RDF) was obtained from Adria Laboratories 
(Mississauga, Ontario). Na125I and ACS scintillation fluid 
was purchased from Amersham (Oakville, Ontario). 
[la,2ce(n)-3H]Cholesteryl hexadecyl ether, 1.48-2.22 
TBq/mmol (3H-CHE) was purchased from New England 
Nuclear (Mississauga, Ontario). Fetal bovine serum was 
purchased from Gibco BRL (Burlington, Ontario). Centri- 
con 100 (M r cut-off 100000) concentrators were pur- 
chased from Amicon (Beverly, MA). Falcon 6-well and 
Coming 96-well plates were purchased from Becton Dick- 
inson (Lincoln Park, N J), and Coming (Coming, NY), 
respectively. Bio-Rad protein microassay kit was pur- 
chased from Bio-Rad Laboratories (Hercules, CA). The 
cell line KLN 205 (murine squamous lung carcinoma) was 
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a generous gift of Biomira, Edmonton, Alberta. The mam- 
malian squamous carcinoma mAb 174H.64 [26] (IgG 1, 
recognizing KLN 205), and the pan adenocarcinoma Ab 
170H.82 [27] (IgG 1, recognizing HCT-15) were generous 
gifts of Biomira. The human colon adenocarcinoma cell 
line HCT-15 (also binding with mAb 170H.82) was pur- 
chased from American Type Tissue Culture (Rockville, 
MD). All other chemicals were analytical grade. 
2.2. Preparation of  antib,odies 
Monoclonal antibody solutions were concentrated and 
the storage buffer exchanged with 25 mM Hepes, 140 mM 
NaC1, pH 7.4 (Hepes buffer), using a Centricon 100 
concentrator (Amicon, USA) by centrifugation at 3000 
rpm in a Sorvall $34 rotor. Protein content was determined 
for the concentrated solution using the Bio-Rad protein 
microassay kit. 
For preparation of iodinated Ab, solutions (10 mg/ml) 
of sheep IgG, bovine IgG, 174H.64 mAb or 170H.82 mAb 
were prepared in Hepes buffer. The Ab solution (200-300 
/zl) was then mixed with 185 MBq of Na125I in a 2 ml 
reaction vial with 7 Iodo-Beads (Pierce, Rockford, IL) at 
22°C for 1 h. The resulting ~2Sl-Ab was desalted by gel 
filtration over Sephadex G-25 in the above buffer. 
Thiolated Ab was prepared from an Ab solution (10 
mg/ml) in Hepes buffer containing a trace amount of 
125I-Ab. PDP-Ab was formed by adding SPDP (25 mM in 
95% ethanol) slowly to the antibody solution at a 
SPDP/Ab molar ratio c f 10:1, and the mixture was then 
incubated for 30 min at 22°C. Unbound SPDP was re- 
moved, and the pH was lowered, by passing the Ab 
mixture over a Sephadex G-50 column eluted with 100 
mM sodium acetate, 100 mM NaC1, pH 4.7. The PDP 
group on the antibody was then reduced (forming a thiol 
group) by adding DTT at a final concentration of 20 mM 
DTT. DTT was removed by passing the thiolated Ab over 
a Sephadex G-50 column with 25 mM Hepes, 25 mM 
Mes, 140 mM NaCI, pH 6.7. 
The extent of PDP substitution on the PDP-Ab was 
determined by measuring the release of 2-thiopyridone 
(00343 = 8300 M -1 cm-  1) at OD 343 nm after reduction of 
the PDP-Ab with 20 l~  DTT. 
Maleimide-Ab (MPB-Ab) was prepared by adding 
SMPB (25 mM in dimethylformamide) slowly to an anti- 
body solution (10 mg/rnl in Hepes buffer) at a molar ratio 
of 20:1, SMPB/Ab, then incubated for 1-2 h at 22°C. 
Unbound SMPB was removed by passing the MPB-Ab 
over a Sephadex G-50 column and eluted with 25 mM 
Hepes, 25 mM Mes, 140 mM NaC1, pH 6.7. 
The number of maleimide residues was determined 
indirectly by assaying for the binding to MPB-Ab of a 
thio-containing fluorescent probe, SAMSA fluorescein (5- 
((2-(and 3-)-S-(acetylmercapto)succinoyl)amino)fluo- 
rescein, Aex495 nm and )tern520 nm, Molecular Probes, 
Eugene, OR). SAMSA fluorescein binds to maleimide 
residues in a 1:1 molar ratio. SAMSA fluorescein (2 mg) 
was dissolved in 200 /.d of 0.1 M NaOH. After 15 min at 
22°C the solution was neutralized with 2 /zl of 6 M HC1 
and 40 /xl of 0.5 M NaPO 4, pH 7.0, buffer. The activated 
probe was then incubated at a 10-times molar excess with 
MPB-Ab for 2 h at 22°C. Unbound SAMSA fluorescein 
was removed by using a Sephadex G-25 column equili- 
brated with Hepes buffer. The degree of SAMSA fluores- 
cein substitution of the labelled Ab was determined by 
measuring the absorbance at 495 nm on a Titertek Multi- 
skan PLUS MK II plate reader (Flow Laboratories, Missis- 
sauga, Ontario, Canada) and interpolating from a SAMSA 
fluorescein standard curve or calculating from the molar 
extinction coefficient of 80 000 cm- ~ M- ~ at 495 nm (the 
molar extinction coefficient of SAMSA fluorescein did not 
appear to change significantly in the presence of bound 
Ab). 
Oxidized Ab was prepared by a modification of the 
procedure of Chua et al. [15] by oxidizing the carbo- 
hydrates on the Fc portion of the antibodies through 
addition of sodium periodate (0.2 M in distilled H20) to 
the Ab solution (10 mg/ml in 123 mM sodium citrate, pH 
5.5) to give a final periodate concentration of 10 mM. 
After 1 h at 22°C, periodate was quenched with 50 mM 
N-acetylmethionine (0.5 M in distilled H20). 
Biotinylated Ab was prepared by incubating N- 
hydroxysuccinimide-biotin (20 mg/ml in dimethylsulf- 
oxide) with the Ab (5 mg/ml) at a ratio of 5:1 (w/w) at 
room temperature for 4 h. Unbound material was separated 
by gel filtration over a Sephadex G-25 column using l0 
mM Tes, 150 mM NaC1, pH 7.4 buffer. 
2.3. Liposome preparation 
Liposomes were composed of HSPC/CHOL (2:1 molar 
ratio) with or without various amounts of mPEG-DSPE 
and with or without he following linker lipids: PDP-PEG- 
DSPE, Hz-PEG-DSPE, PDP-DOPE, MPB-DOPE or bio- 
tinylated PE. In some experiments race amounts of 3H- 
CHE were added as a lipid label. Liposomes were prepared 
by hydrating dried lipid films in an appropriate buffer at a 
phospholipid concentration of 10 mM. Using a Lipex 
extruder (Lipex Biomembranes, North Vancouver, BC), 
the liposomes were passed through 0.1 p~m polycarbonate 
membranes (Nuclepore, Pleasanton, CA or Poretics, Liver- 
more, CA) to give primarily unilamellar vesicles of ap- 
prox. 100 nm in diameter [28,29]. The average size of the 
liposomes were measured by dynamic light scattering us- 
ing a Brookhaven BI90 submicron particle sizer 
(Brookhaven I struments, Holtsville, NY). 
2.4. Doxorubicin loading and leakage 
DXR was loaded into liposomes via an ammonium 
sulfate gradient [30]. Briefly, liposomes were hydrated at 
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10 mM phospholipid in 155 mM ammonium sulfate, pH 
5.5. The external buffer was exchanged by passing the 
liposomes over a Sephadex G-50 column and eluting with 
123 mM sodium citrate, pH 5.5. DXR was then incubated 
with the liposomes (0.2 mg DXR per mg phospholipid) for 
1 h at 65°C. Any unloaded DXR was separated over 
Sephadex G-50 in the appropriate buffer and the amount of 
DXR was determined from its absorbance at 492 nm. 
Leakage of DXR from the liposomes was measured by 
dialysing the DXR liposomes in 25% human plasma gainst 
a large volume of 25% human plasma at 37°C, sampling 
the contents of the dialysis bag at increasing time intervals 
and determining the absorbance as above. 
2.5. Antibody conjugation 
Liposomes (HSPC/CHOL, 100 nm diameter), contain- 
ing 0.1 mol% biotin-DOPE, were hydrated in 10 mM Tes, 
150 mM NaCI, pH 7.4 buffer and incubated with avidin at 
a biotin-DOPE to avidin molar ratio of 1:1 for 30 min at 
22°C (Fig. 1A). Unbound avidin was removed by gel 
filtration using Sepharose CL-4B and the above buffer. 
The avidin-liposomes were then mixed for 30 min at 22°C 
with biotin-Ab at a 1:1000 (biotin-Ab/PL) molar ratio. 
Liposomes (HSPC/CHOL, 100 nm diameter) contain- 
ing either PDP-DOPE (Fig. 1C) or PDP-PEG-DSPE (Fig. 
1E) were prepared in either Hepes buffer or 155 mM 
ammonium sulfate (pH 5.5) when DXR was to be loaded 
into the liposomes. The PDP groups were reduced to form 
free thiols by adding DTr  to the liposomes to give a final 
concentration of 20 mM DTT and the preparations were 
incubated for 30 min at room temperature, DTT was 
separated by passing the liposomes over a Sephadex G-50 
column and eluting with 25 mM Hepes, 25 mM Mes, 140 
mM NaCl, pH 6.7. The thiolated liposomes were then 
incubated overnight at 22°C with MPB-Ab. 
Liposomes (HSPC/CHOL, 100 nm diameter) contain- 
ing MPB-DOPE (Fig. 1B) or Hz-PEG-DSPE (Fig. 1D) 
were prepared in 25 mM Hepes, 25 mM Mes, 140 mM 
NaC1, pH 6.7 buffer or 123 mM sodium citrate, pH 5.5 
buffer, respectively. For DXR loading experiments, these 
liposomes were prepared with 155 mM ammonium sulfate 
(pH 5.5). MPB-DOPE or Hz-PEG-PE liposomes were 
mixed with thiolated-Ab or oxidized-Ab respectively, and 
incubated overnight at 22°C. 
In each case, unbound antibody was removed by pass- 
ing the Ab-liposome mixture over a Sepharose CL-4B 
column in Hepes buffer. Conjugation results were ex- 
pressed as p,g bound Ab per /~mol ~hospholipid as rou- 
tinely determined by assaying for H-CHE (lipid) and 
125I-Ab. In some instances phospholipid assay was also 
performed according to method of Bartlett [31]. Protein 
concentration i  solutions of free Ab, prior to conjugation, 
was in some instances determined by the Bio-Rad protein 
assay. 
2.6. ELISA (antibody capture assay) 
Bovine IgG (antigen) was plated on 96 well plates at 
500 ng per well (100 /xl, 5 /zg IgG/ml in Hepes buffer) 
and was allowed to stand overnight. After washing three 
times with Hepes buffer, excess binding sites were satu- 
rated with 200/.d of 0.8% gelatin in distilled H20 for 2 h 
at 22°C. Rabbit anti-bovine IgG (primary antibody) was 
modified with SPDP, SMPB or periodate as described 
above. In a separate xperiment, oxidized antibody was 
incubated at various concentrations with hydrazide lipo- 
somes (HSPC/CHOL/Hz-PEG-DSPE, 2:1:0.1 molar ra- 
tio) to achieve a range of Ab densities at the liposome 
surface. The plates were washed five times with Hepes 
buffer and the PDP-Ab, MPB-Ab, oxidized Ab or Ab-lipo- 
somes were plated at 1.25-40 ng per well or 0.025-0.8 
mM phospholipid per well for 2 h at 22°C. After washing 
the plates, mouse anti-rabbit horse radish peroxidase con- 
jugate was added to each well for 2 h at 22°C. The plates 
were then washed as above, and colour was developed by 
adding either the substrate TMB (3,3',5,5'-tetramethylbe- 
nzidine, Gibco BRL, Gaithersburg, MD) or ABTS (2,2'- 
azino-bis(3-ethylbenzothiazoline)-6-sulfonic acid, KPL, 
Gaithersburg, MD). The plates were read after 10-30 min 
at OD 650 nm (TMB) or OD 405 nm (ABTS) on a 
Titertek Multiskan PLUS MK II plate reader (Flow Labo- 
ratories, Mississauga, Ontario). 
2. 7. In vitro cell binding studies 
Binding of immunoliposomes to cultured cells was 
compared for three different coupling procedures (MPB- 
DOPE, Hz-PEG-DSPE and PDP-PEG-DSPE). Murine 
squamous lung carcinoma (KLN 205) and human colon 
adenocarcinoma (HCT-15) cells were grown as monolay- 
ers in RPMI 1640 media. Media was supplemented with 
10% fetal bovine serum, and cells were maintained at 37°C 
in a humidified atmosphere of 5% CO 2 in air. On day l, 
cells were plated in triplicate into 6-well plates at (1.5-2) • 
l05 cells/welI. SIL were prepared as above by conjugat- 
ing mAb e i ther  to the PEG terminus  
(HSPC/CHOL/mPEG-DSPE/PDP-PEG-D SPE, 
2:1:0.08:0.02 or HSPC/CHOL/Hz-PEG-DSPE, 2:1:0.1 
molar ratio), or to the maleimide group on the surface of 
SL (HSPC/CHOL/mPEG-DSPE/MPB-DOPE,  
2:1:0.1:0.02). The mAb were specific to each cell line, i.e., 
mAb 174H.64 coupled to SL (SIL[174H.64]) for experi- 
ments with the KLN 205 cell line, or 170H.82 coupled to 
SL (SIL[170H.82]) for experiments involving the HCT-15 
cell line. On the fourth day SlL[174H.64] or SIL[170H.82] 
(0.1-0.4 /xmol PL/ml Hepes buffer), labelled with 3H- 
CHE, were added to each well of the appropriate cell lines. 
After 1 h incubation at 37°C, cells were washed three 
times with phosphate-buffered saline, pH 7.4, trypsinized 
with 0.5 ml of 0.05% trypsin, and the levels of bound 
3H-CHE-labelled liposomes were determined by placing 
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the cells in ACS scintillation fluid, and counting in a 
Beckman LS-6800 counter. Competition for binding to 
KLN 205 cells between free mAb and liposome-coupled 
specific mAb or isotype-matched non-specific antibodies 
(NSAb) (B27.29, an murine IgG 1 from Biomira), coupled 
via the PDP-PEG-DSPE method, was determined by addi- 
tion of 20-fold excess of free Ab 10 min before adding 
3 H-CHE-labelled SIL. 
A.  Biotin-DOPE 
Ab--Biotin ~- Avidin -[- Biotin--Liposomes 
Biotinylated antibody Biotinylated liposomes 
Ab--Biotin --Avidin --Biotin --Liposomes 
Immunoliposomes 
D.  MPB-DOPE O 
Ab--SH "[" ~oN--~"~CH2)3--~I--NH--DOPE--Lipos°mes 
Reduced 
PDP-antibody MPB-PE liposomes 
o o 
II 
CH2)3--C--NH--DOPE--Liposomes 
Ab--S 0 
Immunoliposomes 
C.  PDP-DOPE 
O 
Ab--oS/~ ~ "l- 
MPB-antibody 
'~  S--S----~CH2)2--C--NH--DOPE ---Lip °s°mes 
, o 
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O 
Ab- -N~ 
O 
O S----(CH2)  --C--NH--DOPE--Liposomes 
Immunotiposomes 
D,  Hz-PEG-DSPE 
O O O 
II II II 
Ab---CHO -~- NH2NH--C--CH 2-NH-C-O-[(CH2)2-O]n--C-NH-DSPE-Liposomes 
Oxidized ~ndbody 
E.  PDP-PEG-DSPE 
AbO~ 
o)  l, + 
MPB-~tib~y 
Hydrazide-PEG-PE liposomes l 
O O O 
II II II 
Ab--CH=NNH--C--CH 2-NH-C--O-[(CH2)2--O]n--C-NH-DSPE-Liposomes 
Immunoliposomes 
O O 
x II II 
S--S---(CH2) 2-C-NH----[(CH2)20]n --C--NH--DSPE --Liposomes 
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o 
Ab- -N~ O O 
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Immunoliposomes 
Fig. 1. Schematic diagram of the different coupling methods between SL and Ab. (A) biotin-avidin, (B) MBP-DOPE, (C) PDP-DOPE, (D) Hz-PEG-DSPE 
(E) PDP-PEG-DSPE. 
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3. Results 
3.1. Coupling antibodies to sterically stabilized liposomes: 
comparison of the different methods 
The basic reaction schemes for the four covalent cou- 
pling methods and the non-covalent biotin-avidin method 
are diagrammed in Fig. 1. In the biotin-avidin method, 
avidin, with its four biotin binding sites, functions to 
crosslink biotinylated Ab to biotinylated lipid at the lipo- 
some surface. The MPB-DOPE and PDP-DOPE methods 
involve the formation of a covalent thioether bond between 
thiol and maleimide groups, near the liposome surface, 
while the PDP-PEG-DSPE method involved the formation 
of a thioether bond at the PEG terminus. In the fourth 
method a covalent hydrazone bond is formed between a 
oxidized carbohydrate in the Fc region of an Ab and a 
hydrazide group at the PEG terminus on the liposome. 
For the preparation of SL, the total PEG-lipid content 
was always maintained at 5 mol% of the phospholipids 
(PL), i.e., HSPC. Liposomes containing 5 mol% Hz-PEG- 
DSPE, therefore, contained no mPEG-DSPE. All linker 
lipids incorporated readily into liposomes and resulted in 
no alterations in liposome size or stability (results not 
shown). The complete incorporation of both PDP-DOPE 
and PDP-PEG-DSPE at a concentration of 1 mol% PL was 
shown by the 100% release of 2-thiopyridone from lipo- 
somes following reduction of PDP with DTT as deter- 
mined spectrophotometrically. 
Table 1 compares the /~g sheep IgG bound to the 
liposomes per /zmol phospholipid for the non-covalent 
biotin-avidin method, and the four covalent coupling meth- 
ods in the presence and absence of mPEG-DSPE. Linker 
lipids were incorporated into liposomes at 1 mol% of PL 
content except for Hz-PEG-DSPE which was incorporated 
at 5 mol% of PL and biotin-DOPE which was incorporated 
at 0.1 mol% of PL. Using the biotin-avidin method, low 
levels of Ab attached to the liposome surface (14 p~g 
Ab//zmol PL) with low efficiency. For the MPB-DOPE 
and PDP-DOPE methods where the antibody is bound to 
the liposome surface, in the absence of mPEG-DSPE, 
comparably high amounts of protein were bound to the 
liposomes (112 and 108 /xg Ab//zmol PL, respectively). 
An insignificant reduction occurred in the amount of Ab 
bound to MPB-DOPE liposomes in the presence of 
mPEG-DSPE (97 /~g Ab//zmol PL). However, when 5 
mol% mPEG-DSPE was incorporated into PDP-DOPE- 
liposomes a 72% reduction in Ab binding occurred (15 /zg 
Ab//xmol PL), likely a result of steric hinderance by PEG 
to the access of the MPB-Ab to the small thiol group at the 
liposome surface. Furthermore, when the conjugation reac- 
tion occurred at the PEG terminus using PDP-PEG-DSPE, 
which has the same reaction chemistry as the PDP-DOPE 
method, conjugation was not hindered by PEG (96 and 93 
/zgAb//xmol PL in the presence or absence of 4 mol% 
mPEG-DSPE, respectively). All coupling reactions involv- 
ing the formation of a thioether bond, with the exception 
of the PDP-DOPE method in the presence of mPEG-DSPE, 
had a coupling efficiency of approx. 60-70% at compara- 
ble reaction conditions (Table 1). Although the Hz-PEG- 
DSPE method was the simplest of the coupling methods, 
Ab densities (25.7 /xg Ab//xmol PL) and coupling effi- 
ciencies (17%) were lower than for the MPB-DOPE and 
PDP-PEG-DSPE methods. Indeed, when the linker lipid 
Hz-PEG-DSPE was included in the liposomes at 1 mol%, 
Ab levels associated with the liposomes were not signifi- 
cantly elevated above background levels, therefore all 
experiments were done with 5 mol% Hz-PEG-DSPE in the 
liposomes. 
Table 1 also shows the amount of DXR loaded in 1 h 
by an ammonium sulfate gradient method [30] into lipo- 
somes containing linker lipids, with and without mPEG- 
DSPE. DXR could be loaded efficiently (> 95%) at 65°C 
into all liposomes except those containing MPB-DOPE 
Table 1 
Effect of coupling method and mPEG on binding of Sheep IgG to liposomes 
Liposome composition a mol% Ab binding Binding approx. No. Ab DXR loading 
(molar atio) mPEG /xg//xmol PL efficiency (%) per liposome b (%) 
HSPC/CHOL/biotin-DOPE (2:1:0.002) 5 
HSPC/CHOL/MPB-DOPE (2:1:0.02) 5 
0 
HSPC/CHOL/PDP-DOPE (2:1:0.02) 5 
0 
HSPC/CHOL/PDP-PEG-DSPE (2:1:0.02) 4 
0 
HSPC/CHOL/Hz-PEG-DSPE (2:1:0.02) 0 
14+5 9+3 7+3 >95 
97 + 15 63 + 10 49 + 8 variable c 
113 + 11 72 + 7 56 + 6 variable c 
15_+ 1 10+ 1 7-1- 1 >95 
108_11 69_+7 54±5 >95 
96 + 22 61 + 14 48 + 11 > 95 
93 60 46 > 95 
26+4 17 + 3 13 +2 > 95 
a Liposomes preparation, conjugation procedures and DXR loading were according to Section 2. Sheep IgG was coupled to 100 nm liposomes at an 
Ab/PL molar ratio of hl000, and a phospholipid concentration of 2 mM. The total PEG content of the liposomes was kept constant at 5 mol% of PL. 
DXR was loaded at 65°C for 1 h. 
b The conversion from ~g IgG//~mol phospholipid to the approximate number of Ab per liposomes was based on the following assumptions: the area per 
2 2 polar head group for HSPC is 72 ,~ and for CHOL is 19 ,~ [2] with a combined area per phospholipid for a 100 nm, HSPC/CHOL (2:1, mol/mol) 
liposome of 81.5 ~2 and that there are approx. 4 • 10 ~2 antibodies per/xg protein and 7.8 - 10 j2 liposomes per/zmol PL. 
c A precipitate of DXR was often observed, complicating the calculations (see text). 
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Table 2 
% DXR loading into liposomes as a function of mol% MPB-PE 
Mol% MPB-DOPE % DXR loading, 
in liposomes 1 h at 65°C 
1.0  40 
0.5 73 
0.1 80 
0.05 > 95 
0 > 95 
to 1.0 mol% of PL resulted in a 5-fold increase in the 
amount of bound Ab (Fig. 2A). Similarly, as the Ab/PL 
ratio increased the total amount of bound Ab also in- 
creased substantially (Fig. 2B). Fig. 2C demonstrates that 
coupling is much less dependent on PL concentration than 
on the concentration of linker lipid or Ab. A 5-fold 
increase in PL concentration during Ab coupling resulted 
in only a 1.5-fold increase in Ab binding. 
(i.e., the comparatively large, hydrophobic MPB group at 
the liposome surface) where DXR loading was highly 
variable and unpredictable, ranging from a maximum of 
40% loading at 1 mol% MPB-DOPE to > 95% of the 
initial DXR entrapped at 0.05 mol% MPB-DOPE or less 
(Table 2). With the ammonium sulfate loading method at 1 
mol% MPB-DOPE in the liposomes, a DXR precipitate 
was sometimes observed which complicated the calcula- 
tion of the % entrapped (or associated) DXR. This is 
thought o be caused by DXR reacting with ammonium 
sulfate leaking from the liposomes in the presence of 1 
mol% MPB-DOPE (but not lower concentrations of MPB- 
DOPE) to form a (DXR-.NH3)2SO 4 complex which has a 
low solubility [32,33]. The difficulties experienced with 
DXR remote loading in the presence of 1 mol% MPB- 
DOPE in the liposomes also occurred when we employed 
the pH gradient method [34]. Increasing the incubation 
time to 6 h in the presence of 1 mol% MPB-DOPE could 
sometimes increase the amount of DXR loading, but this 
was highly variable, and we have not yet been able to 
determine if the DXR was in the liposome interior or 
associated with the bilayer. Furthermore, longer incubation 
times at high temperatures led to the degradation of some 
of the maleimide groups, compromising Ab coupling effi- 
ciency (results not shown) ~ In contrast, for the PDP- 
PEG-DSPE method, DXR loading was > 95% and the 
7"i/2 for DXR leakage in 25% human plasma at 37°C was 
approx. 88 days in the unconjugated liposomes and over 
15 days in the conjugated liposomes (88 /zg sheep 
IgG//xmol PL). 
3.2. Factors affecting Ab coupling efficiency 
We have investigated, for the MPB-DOPE method, 
three main factors affecting coupling of Ab to SL: (1) the 
concentration of linker lipid incorporated into the lipo- 
somes, (2) the Ab concentration a d (3) the lipid concen- 
tration during the coupling reaction (Fig. 2A-C). A 10-fold 
increase in the amount incorporated MPB-DOPE, from 0.1 
I Not only did we have problems with the loading and leakage of DXR 
in the presence of 1 mol% MBP-DOPE, but we could not perform 
biodistribution experiments with these liposomes using ]~5I-tyraminy- 
linulin as an aqueous pace label because it bound to the outside of the 
liposomes. 
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Fig. 2. Factors affecting the coupling of Ab (sheep IgG) to SL (MPI~- 
DOPE method). Liposomes were 100 nm in diameter, composed of 
HSPC/CHOL/mPEG-DSPE, 2:1:0.1 molar ratio. PDP-Ab (sheep IgG) 
was prepared using SPDP as outlined in Section 2. (A) Effect of 
MPB-DOPE content. Liposomes containing 0 to 1 mol% MPB-DOPE 
were incubated with PDP-Ab at an Ab/PL  molar ratio of 1:1000. (B) 
Effect of Ab concentration. Liposomes (1 mol% MPB-DOPE) were 
incubated with various amounts of Ab at a constant phospholipid concen- 
tration of 2 mM. (C) Effect of lipid concentration. Various concentrations 
of liposomes (1 mol% MPB-DOPE) were incubated with PDP-Ab at a 
molar ratio of 1:1000 (Ab/PL). 
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Fig. 3. Efficiency of sheep IgG binding to SL for different coupling 
procedures. Liposomes (100 nm in diameter) were incubated at 2 mM PL 
with the appropriate Ab at a varying Ab/PL molar ratios. (0 )  
HSPC/CHOL/mPEG-DSPE/MPB-DOPE (2:1:0.1:0.02), (• )  
HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE (2:1:0.08:0.02), (A)  
HSPC/CHOL/mPEG-DSPE/PDP-DOPE (2:1:0.1:0.02), ( I )  
HSPC/CHOL/Hz-PEG-DSPE (2:1:0.1). 
Fig. 3 compares the efficiency of coupling of Ab to SL 
by the various coupling methods. For both the PDP-PEG- 
DSPE and MPB-DOPE methods, maximum coupling effi- 
ciency, approaching 100%, occurred at a Ab/PL ratio of 
approx. 1:1000 or lower, corresponding to an Ab to linker 
lipid molar ratio of about l:10 or lower. Above this ratio a 
steep dependence of % bound Ab on Ab/PL molar ratio 
was observed. As seen previously (Table 1) the coupling 
efficiency for the PDP-DOPE method was low, and in- 
creasing the Ab/PL molar ratio did not lead to a signifi- 
cant increase in coupling efficiency (Fig. 3). The Hz- 
PEG-DSPE method also had lower coupling efficiencies 
than the PDP-PEG-DSPE or MPB-DOPE methods and 
demonstrated a shallow dependence on Ab/PL molar ra- 
tios. 
ng antibody per well 
Fig. 4. Effect of various antibody coupling treatments on binding of 
anti-bovine IgG to bovine IgG-coated ELISA plate wells. The mAb was 
prepared as described in Section 2. (0 )  untreated mAb, (A) sodium 
periodate oxidized mAb, (11) SMPB-treated mAb, (v )  SPDP-treated 
mAb, ( • ) non-specific Ab (sheep IgG). 
compare the degree of binding of SIL to the target antigen 
as a function of both increasing lipid concentration a d Ab 
surface density. A direct dependence, both of Ab surface 
density as well as liposome concentration, was found for 
binding of SIL to their target antigens. In order to examine 
this relationship for cellular epitopes, the effects of liposo- 
mal surface densities of mAb 174H.64 was determined on 
the KLN 205 cell line for both the MPB-DOPE and 
PDP-PEG-DSPE methods as shown in Fig. 6A and B, 
respectively. For both methods the effect of Ab density on 
SIL binding in vitro was modest (Fig. 6A) or appeared to 
be absent (Fig. 6B), as compared to the ELISA experi- 
ments. 
3.5. Binding of SIL, formed by different coupling methods, 
to neoplastic ells 
3.3. Effect of chemical manipulation of an Ab on its 
antigen binding activity 
The comparative binding by KLN 205 cells of 
SIL[ 174H.64], conjugated by two different coupling proce- 
An ELISA was used to determine the affinity of anti- 
bovine IgG (Ab) for bovine IgG (antigen) after treatment 
of the Ab with either SMPB, SPDP or oxidization with 
periodate. The results, over a 40-fold concentration range, 
demonstrate an increase in ELISA signal with increasing 
Ab concentration (Fig. 4). As expected a nonspecific Ab 
(sheep IgG) was not recognized in this assay (Fig. 4). 
Chemical manipulation of the Ab caused a slight loss in 
antigen binding affinity for all methods used, as shown by 
the reduction in ELISA signal at 405 nm (Fig. 4). 
3.4. Effect of Ab surface density on SIL on target binding 
We have used liposomes with increasing amounts of 
bound Ab (Hz-PEG-DSPE method) to investigate the rela- 
tionship between the liposome surface density of Ab and 
the level of target binding. ELISA (Fig. 5) was used to 
-0 .10  , ' . . . .  I . . . . . . .  I 
0.02 0.1 1 
Phoaphollpid (pmollml) 
Fig. 5. Effect of antibody density on binding of SIL[anti-bovine IgG] to 
bovine IgG-coated ELISA plates. Various amounts of oxidized anti-bovine 
IgG was coupled to HSPC/CHOL/Hz-PEG-DSPE (2:1:0.1) liposomes, 
as  described in Section 2. Antibody densities : (O) 52, ( l l )  31, (A) 19, 
(v )  11, (0 )  0 /~g mAb//xmol PL. 
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Fig. 6. Binding of SIL[174H.64] with different antibody surface densities, 
by KLN 205 cells, using MPB-DOPE or PDP-PEG-DSPE coupling 
procedures. PDP-mAb and MPB-mAb were prepared for conjugation as 
described in methods. SIL were labelled with 3H-CHE and incubated for 
1 h at 37°C with KLN 205 cells at a liposome concentration f 0.1-0.4 
/xmol PL /ml .  (A) HSPC/CHOL/mPEG-DSPE/MPB-DOPE 
(2:1:0.1:0.02); (O) 150, (• )  67 (v )  26 and (• )  0 /xg mAb/Fmol  PL. 
(B) HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE (2:1:0.08:0.02), ( • ) 
78, ( • ) 39 and ( • ) 0/xg mAb//xmol PL. Binding is expressed as pmol 
PL/mg cell protein. Means-t-S.D., n= 3. 
dures (Hz-PEG-DSPE and PDP-PEG-DSPE), is shown in 
Fig. 7. The PDP-PEG-DSPE method resulted in signifi- 
cantly increased binding of SIL to KLN 205 cells, as 
compared to controls, while the HZ-PEG-PE method gave 
poor binding results with this model system, even with 
almost twice the Ab surface density (Fig. 7). In experi- 
ments where we incubated free mAb174H.64 for different 
times with increasing concentrations of periodate, we have 
observed that this particular mAb, unlike some other mAb 
or sheep IgG (Fig. 4) Jloses its binding activity under 
oxidizing conditions, which explains the low binding to its 
target cells for the Hz-PEG-DSPE method. 
The binding of SIL[170H.82], formed by three coupling 
procedures at similar Ab densities, by HCT-15 cells is 
shown in Fig. 8. The PDP-PEG-DSPE and MPB-DOPE 
methods resulted in significantly increased binding (ap- 
proximately double) of SIL for both cell lines, while the 
HZ-PEG-PE method, while resulting in increased binding, 
was not as high as the other two methods (approx. 1.5-fold). 
Phospholipid (pmol/ml) 
Fig. 7. Comparative binding of SIL[174H.64], prepared by two different 
coupling procedures, by KLN 205 cell line. Preparation of liposomes and 
the mAb 174H.64 for conjugation and binding procedures are described 
in Section 2. (v ) ,  HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE 
(2:1:0.08:0.02), 34 /xg mAb//zmol PL; (• )  HSPC/CHOL/Hz-PEG- 
DSPE (2:1:0.1), 66 mg mAb//zmol PL; (• )  HSPC/CHOL/mPEG- 
DSPE (2:1:0.1), no mAb. Binding is expressed as pmol PL/mg cell 
protein. Means ___ S.D., n = 3. 
To investigate whether enhanced binding of liposomes 
was through specific recognition of antibodies, competition 
studies were performed, using the PDP-PEG-DSPE method, 
and results are shown in Table 3. SIL[174H.64] had signif- 
icantly higher binding to KLN 205 cells than control 
liposomes with no antibody, or liposomes attached to an 
isotype-matched non-specific Ab SIL[B27.29]. Incubation 
of KLN 205 cells with SIL[174H.64] in the presence of a 
20-fold excess of free mAb174H.64 caused a significant 
reduction in binding, while incubation with excess of free 
mAb B27.29 caused no signification reduction in binding. 
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Fig. 8. Comparative binding of SIL[170H.82], prepared by three different 
coupling procedures, by the HCT-15 colon adenocarcinoma cell line. SIL 
were labelled with 3H-CHE and incubated with cells for 1 h at 37°C with 
cells at a liposome concentration of 0.1-0.4 /~mol PL/ml media. (O) 
HSPC/CHOL/mPEG-DSPE/MPB-DOPE (2:1:0.1:0.02), 59 ~g 
rnAb//zmol PL; (• )  HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE 
(2:1:0.08:0.02), 63 /zg mAb//zmol PL; (• )  HSPC/CHOL/Hz-PEG- 
DSPE (2:1:0.1), 66 /zg mAb//xmol PL; (• )  HSPC/CHOL/mPEG- 
DSPE (2:1:0.1), no mAb. Binding is expressed as pmol PL/mg cell 
protein. Means + S.D., n = 3. 
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4. Discussion 
The rapid removal of CIL from circulation has greatly 
limited their use for in vivo target binding to cells such as 
cancer cells. Several recent studies have demonstrated that 
immunoliposomes could achieve significantly increased in 
vivo target binding when the immunoliposomes contained 
either GM 1 or PEG, which increased their circulation 
half-lives [35-37]. In these studies mAb was associated 
with liposomes by methods such as the N-glutaryl PE 
detergent dialysis method [14,35] or the non-covalent bi- 
otin-avidin method [25,37]. We have previously demon- 
strated that increased target binding in vitro can lead to 
increased cytotoxicity [38] and in vivo can lead to im- 
proved therapeutic effects [37]. Although good target bind- 
ing could be obtained by attaching Ab in the phospholipid 
headgroup region of SL, target recognition was sensitive to 
the chain length of PEG incorporated into the liposomes 
[39,40]. Moil et al. [39] have shown that this steric barrier 
effect is directly related to the chain length of PEG. They 
reported that target binding of immunoliposomes to the 
surface of vascular endothelial cells in the lung was re- 
duced for liposomes containing PEG5000-DSPE but not 
for the smaller molecule GM l or lower molecular weights 
of PEG. When Ab was attached to functional groups at the 
surface of liposomes containing PEG5000, the PEG sub- 
stantially prevented antibody recognition of antigens as 
determined by an ELISA assay [41]. However when the 
length of the PEG is reduced to PEG2000, the size of the 
Ab molecule (molecular weight 150000) appears to be 
sufficient o allow it to bind antigens to a similar degree to 
that found for liposomes lacking PEG-DSPE [41]. 
The mechanism by which PEG-lipids prolong the circu- 
lation times of liposomes is proposed to be that of impart- 
ing a hydrophillic steric barrier to the surface of the bilayer 
[9,42] which is thought o prevent binding of serum protein 
opsonins to the liposome surface [43,44]. PEG may, by a 
similar mechanism, interfere with the binding of Ab or 
avidin to the surface of SL, resulting in the low binding 
efficiency which we have observed for some of the cou- 
pling methods. However, covalent binding of antibodies to 
the PEG terminus does not appear to cause any interfer- 
ence with antibodies binding to their respective antigens, 
and furthermore, the PEG coating of the liposome surface 
apparently continues to retard opsonization of the lipo- 
somes, leading to the extended circulation half-lives which 
we observed for SIL as compared to CIL [23]. Thus the 
Hz-PEG-DSPE and the PDP-PEG-DSPE coupling methods 
have significant advantages over other methods for binding 
Ab to SL. The observation that ligands can be coupled to 
the PEG terminus with retention of the circulation half-lives 
and binding affinity has also been made for other proteins 
[45]. 
The Hz-PEG-DSPE method has the advantage of being 
the simplest of the coupling methods and, because binding 
occurs through oxidized carbohydrate in the Fc region of 
the antibody, is the only method in which Ab orientation is
maintained [15] (i.e., no modification of the Fab binding 
region occurs). This, therefore, would be the method of 
choice where lack of interference with the Fab binding 
region and/or site-specific onjugation were important 
experimental parameters. Rodwell et al. [46] has shown 
increased localization of ill in_labelled Ab conjugates in 
target tumours when modification and conjugation oc- 
curred through a oligosaccharide label when compared to 
methods using direct amino acid labels. However, the 
formation of the hydrazone bond is much less efficient hat 
the formation of a thioether bond, which is reflected in the 
lower coupling efficiencies seen for the Hz-PEG-DSPE 
method compared to the PDP-PEG-DSPE coupling method. 
By ELISA, modification of the antibodies by the vari- 
ous coupling methods resulted in only a modest reduction 
of Ab activity (Fig. 4) using rabbit anti-bovine IgG. How- 
ever, SIL prepared by the Hz-PEG-DSPE method had little 
binding to KLN 205 cells or HCT-15 cells as compared 
either to the MPB-DOPE or the PDP-PEG-DSPE methods 
(Figs. 7 and 8). In other words, some antibodies appear to 
be more sensitive than others to the oxidizing conditions of 
this method. In other targeting experiments, e.g., those 
involving binding of SIL[anti-CD19] to B cells, however, 
we have achieved similar target binding for both the 
Hz-PEG-DSPE and the PDP-PEG-DSPE methods [47]. 
Although the binding results were consistent within each 
model system studied, the variation between systems ug- 
gests that each Ab should be examined for its sensitivity to 
oxidation before use of the Hz-PEG-DSPE method. 
Ideally, we would want to achieve close to 100% 
coupling efficiencies for an Ab coupling method in order 
not to waste mAb, which can be very costly to produce. 
The coupling method which best meets this criteria uses 
one of the most stable and efficient reactions in conjugate 
chemistry, the formation of a thioether bond by interaction 
of sulfhydryl and maleimide groups [16] (Figs. 2 and 3). 
High coupling efficiencies approaching 100% can be 
achieved for both the MPB-DOPE and PDP-PEG-DSPE 
coupling methods when the Ab to linker lipid ratio is 
approx. 1:10 (Fig. 3). 
We were interested to observe that little reduction in 
coupling efficiency was observed for the MPB-DOPE 
coupling method, in contrast to the great reduction in 
efficiency for the PDP-DOPE method, in the presence of 
mPEG-DSPE in the liposomes. Since both approaches 
utilize the same thiol plus maleimide coupling reaction, 
this result is quite surprising. The explanation could lie in 
the difference between the two linker lipids at the lipo- 
some surface. In the PDP-DOPE method, coupling pro- 
ceeds via a thiol group at the liposome surface, which is 
much smaller and more hydrophillic than the MPB group 
in the MPB-PE method. Is it possible that the bulkier, 
more hydrophobic MPB group may cause perturbation of 
the hydrophillic mPEG-DSPE chains, allowing access of 
the thiolated Ab to the liposome surface? The explanation 
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will require further experimentation. As noted above, the 
MPB group also appears to interact with doxorubicin, 
slowing the remote-loading of this drug into liposomes, 
and also results in binding of the aqueous pace marker 
~25I-tyraminylinulin to the liposomes urface, thus prevent- 
ing the use of this marker in pharmacokinetic and biodistri- 
bution studies. In addition, non-specific binding to red 
blood cells of immunoliposomes containing MPB-DOPE 
has been observed and could be overcome by blocking the 
unreacted maleimide with DTT [48]. All four lines of 
evidence point to significant effects of the MPB group at 
the liposome surface at concentrations of 1 mol% of 
phospholipid. These problems can be handled either by 
reducing the mol% of MPB at the liposome surface (which, 
however, decreases coupling efficiencies), by switching to 
a more hydrophilic maleimide-based linker lipid such as 
(N-maleimidomethyl)cyclohexane- l-carboxylate-DOPE 
(MCC-PE) (Avanti Polar Lipids), or by 'reversing' the 
reaction and moving it to the PEG terminus away from the 
liposome surface, i.e., the PDP-PEG-DSPE method. We 
prefer the last solution, as we have been able to achieve 
high coupling efficiencie,;, long circulation times, efficient 
remote-loading of doxorubicin, and good target binding for 
all mAb systems examined with this method, which of all 
the methods we have examined to date comes closest o 
the ideal. 
This study and other:~ suggest hat large amounts of 
bound Ab may not be necessary for efficient arget binding 
of SIL to cells in vitro [35,38] and in vivo [37]. The 
relationship between Ab density and Ab binding seen in 
ELISA studies (Fig. 5) was more pronounced than that 
seen with cells growing in culture (Fig. 6A,B) where many 
of the binding sites may not be accessible to the SIL, 
depending on the degree of cell confluence and the degree 
of attachment of the cells to the substrata. Factors such as 
these may account for th,~ some of the variability between 
level of SIL binding seen in replicate xperiments done on 
different days (e.g., Fig. 6B and 7, and Table 3 for 
SIL[174H,64]). Our obselwations that we have been able to 
achieve higher levels of binding of SIL to cells grown as 
suspension cultures [47] compared to cells grown on solid 
substrates, e.g., this stud}', may be relevant to the choice of 
in vivo targets (see below). If the Ab is sufficiently 
exposed and binding is unhindered by the PEG steric 
barrier, Ab density may not be as critical a factor in the 
efficient binding of immunoliposomes to their target cells, 
as access of SIL to their binding sites. The ability to 
achieve good target binding in vivo at low Ab densities is 
important because the rate of elimination of SIL from 
circulation increases with increased Ab density on lipo- 
somes, particularly above 70-80 /zg Ab//xmol PL [23]. 
Several questions involving in vivo applications of SIL 
remain to be answered. To mention only a few, our ability 
to achieve in vivo targeting will depend on whether the 
target is one accessible from the vasculature [35,36,47], 
where very long circulation half-lives for SIL may be less 
critical, or an extravascular target such as a solid tumor, 
either present as an easily accessible micrometastatic le-
sion, where SIL appear to have good therapeutic effects 
[37], or as a more developed mass, where SIL appear to be 
significantly less effective (experiments in progress). Lo- 
calization of SL (no Ab) in small solid tumors appears to 
increase as the circulation times of the liposomes increases 
[8]. However, in the case of well-developed solid tumors, 
access of SIL, as well as SL, to the bulk of the tumor cells 
may be considerably compromised, and the use of SIL to 
treat advanced solid tumors may not be feasible. Further 
questions about in vivo applications of SIL which need to 
be answered center around: the in vivo stability and toxic- 
ity of the conjugates; the tendency of the SIL to precipitate 
immune reactions, e.g., anti-idiotypic reactions; the rela- 
tive advantages of internalizing versus non-internalizing 
Ab; and the optimum rate of release of drug for the SIL. 
Relevant o the last point are recent experiments by Gaber 
et al. demonstrating that mild hyperthermia c n lead to the 
rapid release of entrapped oxorubicin from SL which 
have localized in tumor microvascular [49]. In other words, 
the rate of release of liposome contents is amenable to 
manipulation, depending on the desired results. 
In summary, we have examined a number of coupling 
methods for covalent or avidin-biotin mediated attachment 
of Ab to the surface of SL, endeavouring to fulfill a 
number of criteria for 'ideal' immunoliposomes. We have 
identified methods which have excellent coupling efficien- 
Table 3 
Competitive binding of SIL[174H.64] in the presence of free mAb 
Liposome composition Binding (pmol PL/mg 
cell protein + S.D.) 
Significance relative to 
binding of SIL[174H.64] 
SIL[174H.64] 792 + 68 
SIL[B27.29] 355 + 63 P < 0.001 
SL (no mAb) 272 + 40 P < 0.001 
SIL[174H.64] + free 174H.64 507 + 40 P < 0.01 
SIL[174H.64] + free B27.29 684 + 179 NS 
KLN 205 cells were grown to confluence in 6-well tissue culture plates, as described in Section 2. SIL, prepared by the PDP-PEG-DSPE method, were 
added to KLN 205 cells 10 rain after a 20-fold excess of the same mAb, or a type-matched non-specific mAb (B27.29), in a total volume of 0.3 ml in each 
well. Concentration f SIL was 0.2 /xmol PL/ml in all wells. Binding (pmol PL/mg cell protein, n = 3) was compared to that of SIL[174H.64] incubated 
with cells in the absence of competing or non-specific mAb. Statistics were done by analysis of variance using the ANOVA program. 
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cies, good drug remote-loading properties, and which re- 
sults in high Ab densities at the liposomes urface. Several 
of these methods result in significantly increased levels of 
binding of SIL to their respective target cells lines. Of the 
methods examined, those in which Ab is attached at the 
PEG terminus appear to have the most useful combinations 
of properties, and in particular we favour the PDP-PEG- 
DSPE method in which a maleimide-modified Ab is cova- 
lently attached to a thiol group at the PEG terminus via a 
thiolether bond. We are currently using both the Hz-PEG- 
DSPE liposomes [47] and the PDP-PEG-DSPE liposomes 
to answer some of the important questions outlined above 
which will help to determine the best therapeutic niches 
for SIL in in vivo applications. 
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